RCUS Earnings Prediction
The chart below shows how RCUS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RCUS sees a +4.99% change in stock price 10 days leading up to the earnings, and a +5.41% change 10 days following the report. On the earnings day itself, the stock moves by -0.68%. This data can give you a slight idea of what to expect for the next quarter's release.
RCUS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
48.00M
50.00%
23.08%
Gross Margin
--
--
--
Operating Margin
-218.75%
-12.50%
-19.52%
Net Margin
-191.67%
-13.62%
-19.62%
EPS
-1.01
-6.32%
-0.98%
No Data Available
RCUS Earnings Analysis
Arcus Biosciences, Inc. Corporation (RCUS.N) Earnings Conference Call
Positive
Cash Balance Increase: 1. Strong Cash Position: Arcus Biosciences reported a cash balance of $1.1 billion at the end of Q3 2024, an increase from $1 billion at the end of Q2 2024, providing a runway into mid-2027.
Quarterly Revenue Increase: 2. Revenue Growth: The company recognized GAAP revenue of $48 million for Q3 2024, up from $39 million in the previous quarter, driven by collaborations with Gilead and Taiho.
Strong Efficacy Results: 3. Promising Clinical Data: The ARC-20 study demonstrated a 34% overall response rate (ORR) in the 100 mg cohort, with a disease control rate (DCR) of 86%, indicating strong efficacy for the HIF-2 alpha inhibitor, Casdatifan.
Long-Lasting Treatment Effects: 4. Durable Responses: In the ARC-20 study, the median progression-free survival (PFS) had not been reached even with 11 months of follow-up, suggesting the potential for long-lasting treatment effects compared to belzutifan's PFS of 5.6 months.
Market Potential Analysis: 5. Market Opportunity: The upcoming PEAK-1 Phase 3 trial for Casdatifan targets an estimated 11,000 patient population in the U.S., representing a market opportunity exceeding $2 billion in the G7 countries.
Negative
Revenue Decline Forecast: 1. Declining Revenue Guidance: The company expects to recognize GAAP revenue of approximately $30 million for Q4 2024, down from $48 million in Q3 2024, indicating a significant decline in revenue expectations.
R&D Expense Increase: 2. Increased R&D Expenses: R&D expenses rose to $123 million in Q3 2024, up from $115 million in Q2 2024, reflecting ongoing financial strain as the company invests heavily in clinical trials without immediate returns.
Stable G&A Expenses: 3. Flat G&A Expenses: General and administrative expenses remained flat at $30 million for Q3 2024 compared to Q2 2024, suggesting a lack of operational efficiency improvements despite rising costs.
Cash Position Decline: 4. Cash Position Decrease: The projected cash and investments balance at the end of 2024 is expected to be between $950 million and $985 million, a decrease from previous guidance of $885 million to $925 million, indicating tighter financial conditions ahead.
Clinical Data Uncertainty: 5. Delayed Clinical Data: The company has not provided specific timelines for the release of critical clinical data from ongoing studies, which may lead to uncertainty among investors regarding the progress of their pipeline.
RCUS FAQs
How does RCUS typically perform around its earnings report dates?
Is Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RCUS Earning Call Sentiment
Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript
RCUS.N
-3.59%Positive
The earnings call summary shows mixed signals. The financial performance is stable with a strong cash position and increased revenue, but there are rising R&D expenses and unclear guidance on pivotal trials. The Q&A section reveals management's reluctance to provide detailed guidance, which could concern investors. However, the collaboration payment from Gilead and stable cash forecast offer some positive aspects. Given the market cap, the stock price is likely to remain stable over the next two weeks, resulting in a neutral prediction.